Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

An monoclonal antibody that binds to EGFRvIII comprising:

• a heavy chain variable region, wherein CDR3 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
• 125, wherein CDR2 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
• 123, wherein CDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
• 121, and wherein the heavy chain variable region comprises an amino acid sequence that is at least 90 percent identical to the light chain variable region of the amino acid sequence in SEQ ID NO:
• 142;
• and
• a light chain variable region, wherein CDR3 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:
• 118, wherein CDR2 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:
• 116, wherein CDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:
• 101, and wherein the light chain variable region comprises an amino acid sequence that is at least 90 percent identical to the light chain variable region of the amino acid sequence in SEQ ID NO:
• 144,
• wherein the monoclonal antibody comprises a murine IgG1 isotype heavy chain comprising the heavy chain variable region,
• wherein the monoclonal antibody comprises a kappa light chain comprising the light chain variable region,
• and wherein the monoclonal antibody does not occur in nature.

A monoclonal antibody that binds to EGFRvIII comprising:

• a heavy chain polypeptide comprising the following complementarity determining regions (CDRs):
• a heavy chain CDR1 that is a CDR1 in SEQ ID NO:
• 2;
• a heavy chain CDR2 that is a CDR2 in SEQ ID NO:
• 2;
• a heavy chain CDR3 that is a CDR3 in SEQ ID NO:
• 2;
• and
• a light chain polypeptide comprising the following CDRs:
• a light chain CDR1 that is a CDR1 in SEQ ID NO:
• 19;
• a light chain CDR2 that is a CDR2 in SEQ ID NO:
• 19;
• and a light chain CDR3 that is a CDR3 in SEQ ID NO:
• 19.

A monoclonal antibody that binds to EGFRvIII comprising:

• a heavy chain variable region, wherein CDR3 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
• 112, wherein CDR2 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
• 110, wherein CDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
• 108, and wherein the heavy chain variable region comprises an amino acid sequence that is at least 90 percent identical to the heavy chain variable region of the amino acid sequence in SEQ ID NO:
• 2;
• and
• a light chain variable region, wherein CDR3 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:
• 105, wherein CDR2 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:
• 103, wherein CDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:
• 101, and wherein the light chain variable region comprises an amino acid sequence that is at least 90 percent identical to the light chain variable region amino acid sequence in SEQ ID NO:
• 19,
• wherein the monoclonal antibody comprises a murine IgG1 isotype heavy chain comprising the heavy chain variable region,
• wherein the monoclonal antibody comprises a kappa light chain comprising the light chain variable region, and
• wherein the monoclonal antibody does not occur in nature.

An assay kit for the detection of EGFRvIII in mammalian tissues or cells, the assay kit comprising:

• a first monoclonal antibody that binds to EGFRvIII comprising:
• (a) a heavy chain polypeptide comprising the following complementarity determining regions (CDRs):
• a heavy chain CDR1 that is a CDR1 in SEQ ID NO:
• 142;
• a heavy chain CDR2 that is a CDR2 in SEQ ID NO:
• 142;
• a heavy chain CDR3 that is a CDR3 in SEQ ID NO:
• 142;
• and
• a light chain polypeptide comprising the following CDRs:
• a light chain CDR1 that is a CDR1 in SEQ ID NO:
• 144;
• a light chain CDR2 that is a CDR2 in SEQ ID NO:
• 144;
• and a light chain CDR3 that is a CDR3 in SEQ ID NO:
• 144;
• or
• (b) a heavy chain polypeptide comprising the following complementarity determining regions (CDRs):
• a heavy chain CDR1 that is a CDR1 in SEQ ID NO:
• 2;
• a heavy chain CDR2 that is a CDR2 in SEQ ID NO:
• 2;
• a heavy chain CDR3 that is a CDR3 in SEQ ID NO:
• 2;
• and
• a light chain polypeptide comprising the following CDRs:
• a light chain CDR1 that is a CDR1 in SEQ ID NO:
• 19;
• a light chain CDR2 that a CDR2 in SEQ ID NO:
• 19;
• and a light chain CDR3 that is a CDR3 in SEQ ID NO:
• 19;
• and
• a labeled second antibody that is anti-immunoglobulin.

A method of using an assay kit for patient selection, the method comprising:

• providing an assay kit for the detection of EGFRvIII in mammalian tissues or cells, the assay kit comprising:
• a first monoclonal antibody that binds to EGFRvIII comprising:
• (a) a heavy chain polypeptide comprising the following complementarity determining regions (CDRs):
• a heavy chain CDR1 that is a CDR1 in SEQ ID NO:
• 142;
• a heavy chain CDR2 that is a CDR2 in SEQ ID NO:
• 142;
• a heavy chain CDR3 that is a CDR3 in SEQ ID NO:
• 142;
• and
• a light chain polypeptide comprising the following CDRs:
• a light chain CDR1 that is a CDR1 in SEQ ID NO:
• 144;
• a light chain CDR2 that is a CDR2 in SEQ ID NO:
• 144;
• and a light chain CDR3 that is a CDR3 in SEQ ID NO:
• 144;
• or
• (b) a heavy chain polypeptide comprising the following complementarity determining regions (CDRs):
• a heavy chain CDR1 that is a CDR1 in SEQ ID NO:
• 2;
• a heavy chain CDR2 that is a CDR2 in SEQ ID NO:
• 2;
• a heavy chain CDR3 that is a CDR3 in SEQ ID NO:
• 2;
• and
• a light chain polypeptide comprising the following CDRs:
• a light chain CDR1 that is a CDR1 in SEQ ID NO:
• 19;
• a light chain CDR2 that is a CDR2 in SEQ ID NO:
• 19;
• and a light chain CDR3 that is a CDR3 in SEQ ID NO:
• 19;
• and
• a labeled second antibody that is anti-immunoglobulin;
• binding the first monoclonal antibody to an EGFRvIII antigen in patient tissues or cells;
• detecting a reaction of the first monoclonal antibody with the EGFRvIII antigen, thereby screening the patient tissues or cells for epithelial cancer;
• and
• selecting the patient as having the epithelial cancer.